London Drugs, one of Canada’s most trusted pharmacy and retail chains, will launch FOCUSfactor brain health supplements across all 80 store locations in Western Canada beginning this summer. The ...

Jon Rice, COO of Kraig Labs, recently traveled to the Company’s production facilities in Southeast Asia to organize the launch of this next exciting phase of Kraig's production plan for 2025 and 2026, ...

The study is scheduled to run through 2026, with Firefly commercially engaged to provide EEG systems, training, and full analytic support, including the comparison to its proprietary, FDA-cleared ...

Recludix Pharma, a leader in the discovery of inhibitors of challenging targets for inflammatory disease, today announced that the company has strengthened its leadership team through: the promotion ...

Anavar for Women is trending in 2025 as fitness-focused women seek safer, effective cutting support. Discover how Anvarol is ...

SINGAPORE, July 14, 2025 (GLOBE NEWSWIRE) -- Gero, an AI-driven biotechnology company focused on developing therapeutics for age-related diseases, today announced the appointment of Brian Kennedy, ...

DURHAM, N.C., July 14, 2025 (GLOBE NEWSWIRE) -- Validic, the platform for Connected Health Data and remote patient monitoring (RPM), today announced the launch of Validic Sparks, a generative AI ...

Proposed transaction creates the broadest, most flexible portfolio of orthopedic robotics and navigation technologies to meet surgeons’ needs. Acquisition expected to be neutral ...

BTIG Virtual Biotechnology Conference Format: Fireside Chat and one-on-one meetings Date: Tuesday, July 29, 2025 Time: 10:00 AM ET Webcast Link: Available on the News & Events page of the I-Mab ...

At the time of the interim analysis, approximately 9% of the women treated in the study had experienced a pregnancy, a rate consistent with the company’s expectations based on the results of the ...

Ascentage Pharma Group International Inc. (NASDAQ: AAPG; HKEX: 6855) (“ Ascentage ” or the “ Company ”), a global biopharmaceutical company dedicated to addressing unmet medical needs in cancers, ...

OMS1620 is advancing through IND-enabling studies for diseases associated with ACTH excess, including congenital adrenal hyperplasia Designed to resist competition from endogenous ACTH by maximizing ...